Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MTTP | P55157 | 9/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | APOB | P04114 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
| ▸ | LDHB | P07195 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2589162 | 0.82 | NPY2R (0.46) | NPY2RGAASMN1; SMN2MTTPKDM4E | |
| SCHEMBL6708421 | 0.80 | NPY2R (0.62) | NPY2RGAAMTTPKDM4EALDH1A1 | |
| SCHEMBL2582758 | 0.79 | NPY2R (0.83) | NPY2RGAASMN1; SMN2MTTPAPOB | |
| SCHEMBL12174384 | 0.79 | NPY2R (0.69) | NPY2RMTTP | |
| SCHEMBL12174502 | 0.78 | NPY2R (0.70) | NPY2RGAAMTTPKDM4EALDH1A1 | |
| SCHEMBL12157792 | 0.78 | NPY2R (0.67) | NPY2RMTTP | |
| SCHEMBL12174486 | 0.78 | NPY2R (0.62) | NPY2RGAAMTTPKDM4EALDH1A1 | |
| SCHEMBL6706746 | 0.77 | NPY2R (0.56) | NPY2RGAASMN1; SMN2MTTPKDM4E | |
| SCHEMBL12174561 | 0.77 | NPY2R (0.57) | NPY2RGAASMN1; SMN2MTTPKDM4E | |
| SCHEMBL2586192 | 0.77 | NPY2R (0.67) | NPY2RMTTP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354402-B2 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-01-15 | — | — | US | disclosed |
| US-20110269747-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | MEERPOEL LIEVEN | 2011-11-03 | — | — | US | disclosed |
| EP-1317431-B1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-20 | — | — | EP | disclosed |
| US-7528154-B2 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICAL N.V. (BE) | 2009-05-05 | — | — | US | disclosed |
| US-20080125412-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | MEERPOEL LIEVEN | 2008-05-29 | — | — | US | disclosed |
| US-7253157-B2 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-07 | — | — | US | disclosed |
| EP-1806341-A2 | (+)Phenyl-(4-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperidin-1-yl)-acetic acid methyl ester as lipid lowering agent | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-11 | — | — | EP | disclosed |
| US-20070082888-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | MEERPOEL LIEVEN | 2007-04-12 | — | — | US | disclosed |
| US-7169796-B2 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-30 | — | — | US | disclosed |
| US-20060241113-A1 | Polyarylcarboxamides useful as lipid lowering agents | MEERPOEL LIEVEN | 2006-10-26 | — | — | US | disclosed |
| US-20050159402-A1 | Polyarylcarboxamides useful as lipid lowering agents | MEERPOEL LIEVEN (BE) | 2005-07-21 | — | — | US | disclosed |
| US-6878724-B2 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN-PHARMACEUTICA N.V. (BE) | 2005-04-12 | — | — | US | disclosed |
| US-20040014971-A1 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159402-A1 | Polyarylcarboxamides useful as lipid lowering agents | LIPC, PNLIP, APOB | NPY2R 4187/4885GAA 476/4885SMN1; SMN2 4407/4885 |
| US-20080125412-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | LIPC, PNLIP, APOB | NPY2R 4187/4885GAA 476/4885SMN1; SMN2 4407/4885 |
| US-20060241113-A1 | Polyarylcarboxamides useful as lipid lowering agents | LIPC, PNLIP, APOB | NPY2R 4187/4885GAA 476/4885SMN1; SMN2 4407/4885 |
| US-20110269747-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | LIPC, PNLIP, APOB | NPY2R 4187/4885GAA 476/4885SMN1; SMN2 4407/4885 |
| US-20040014971-A1 | Polyarylcarboxamides useful as lipid lowering agents | SREBF1, LIPC, CPT1A | NPY2R 4449/4885GAA 769/4885SMN1; SMN2 4160/4885 |
| US-20070082888-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | LIPC, PNLIP, APOB | NPY2R 4187/4885GAA 476/4885SMN1; SMN2 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.